NRT Harm Reduction Indications Need Fast-Track Evaluation – Experts
This article was originally published in The Tan Sheet
Executive Summary
FDA should expedite moving NRT claims from a smoking cessation to a harm reduction framework, experts and stakeholders say. At a public hearing, the agency examined expanded indications for the drugs and the challenges FDA faces with two centers that intersect in the tobacco and cessation space.